Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Methylphenidate
Dopamine transporter inhibitor|Norepinephrine transporter inhibitor
What it measured
Main measures
Score on the Paced Auditory Serial Addition Test (PASAT) one hour after taking the drug/placebo
Thinking and memory
Who could take part
Relapsing and progressive · 25 to 65
Inclusion Criteria: * Diagnosis of definite MS according to Poser criteria; * Attention impairment defined as abnormal PASAT score; * Written and signed informed consent; Exclusion Criteria: * Pregnancy or lactation; * Steroid treatment; * Persistent psychostimulant treatment; * MS relapse;
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Scientific background: Growing awareness and accumulating data regarding the cognitive impairment and its progression in multiple sclerosis (MS) patients has received an important place in neurological research in the last decade.
Loading reviews and guidelines…
Related trials
- Impact of Armodafinil on Neurocognition and Cognitive Fat…
Phase 2 / Phase 3 · Completed
Met its main goal
History
Started
Jun 2003
Finished
Jun 2005
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error